CanAg® CA242™ EIA

The tumor marker CA242™ is defined by the monoclonal antibody C242™. The chemical structure of the antigenic determinant is not exactly known, but the determinant has been shown to be a sialylated carbohydrate structure. In serum, CA242™ is found on the same mucin complex as CA50 and sialylated Lewis A (CA19-9). Thus, CA242™ is related, but not identical to the epitope of CA19-91, 2. Serum levels of CA242 are low in healthy subjects and subjects with benign diseases, while elevated levels are commonly found in serum from patients with gastrointestinal cancer3. The CA242™ marker may be used as an aid in the diagnosis and management of patients with known or suspected gastrointestinal carcinomas4-9. The CanAg Diagnostics CA242 EIA should not be used as a substitute for any established clinical examination of malignancy, but may be used as a complement to existing clinical and laborator methods.

References

  1. Johansson, C., Nilsson, O., Baeckström, D., Jansson, E.-L. and Lindholm, L. (1991) Novel Epitopes on the CA50-Carrying Antigen: Chemical and Immu- nochemical Studies, Tumor Biol., 12, 159-179.

  2. Johansson, C., Nilsson, O. and Lindholm, L., (1991) Comparison of Serological Expression of Different Epitopes on the CA50-Carrying Antigen CanAg, Int. J. Cancer, 48, 757-763.

  3. Nilsson, O., Johansson, C., Glimelius, B., Persson B., Nørgaard-Pedersen, B., Andrén-Sandberg, Å., and Lindholm L. (1992): Sensitivity and specificity of CA242 in gastrointestinal cancer. A comparison with CEA, CA50 and CA19-9. Br J Cancer 65, 215-221.

  4. Dahlén U., Karlsson B., Lindholm L., Nilsson O., (1993) Development of an enzyme immuno-assay for determination of the tumor associated antigen CA242, J. Tumor Marker Oncology 8, 3, p 111.

  5. Kawa, S., Tokoo, M., Hasebe, O., Hayashi, K., Imai, H., Oguchi, H., Kiyosawa, K., Furuta, S., and Homma, T.,(1994) Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer, Br. J. Cancer, 70, 481-486.

  6. Von Kleist, Hesse, Kananeeh, (1996) Comparative Evaluation of Four Tumor Markers, CA 242, CA 19-9, TPA, and CEA in Carcinomas of the Colon, Anti-cancer Research 16: 2325-2332.

  7. Spila A, Ferroni P, Cosimelli M, D'Alessandro R, Abbolito MR, Mariotti S, Aloe S, Carone MD, Graziano F, Tedesco M, Martini F, Mancini R, Stigliano V, Roselli M, Guadagni F. (2001) Comparative analysis of CA 242 and CA 19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation. Anticancer Res. Mar-Apr;21(2B):1263-70.

  8. Carpelan-Holmström, M., Haglung, K., Lundin, J., Järvinen, H and Roberts, P., (1996) Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer. Eur. J. Cancer 32(7), 1156-1161.

  9. Engarås B. (2003 ) Individual cutoff levels of carcinoembryonic antigen and CA 242 indicate recurrence of colorectal cancer with high sensitivity. Dis Colon Rectum. Mar;46(3):313-21.

CE marked
CanAg CA242™ EIA

Product number 101-10

For 96 determinations
Contact sales for information and inquiries
Please contact your local Fujirebio representative for the availability of this product in your country.
  • Product inquiry

    The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

    For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

    If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: privacy@fujirebio.com.